6
Views
0
CrossRef citations to date
0
Altmetric
Practice Pearl

Addition of Extended-Release Niacin to Statin Therapy: Effects on Atherosclerotic Progression

Pages 160-161 | Published online: 13 Mar 2015

References

  • . Grundy SM, Cleeman JI, Merz CN, ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
  • . Gordon DJ, Probstfield JL, Garrison RJ, . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15
  • . Canner PL, Berge KG, Wenger NK. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–1255
  • . Wolfe ML, Vartanian SF, Ross JL, . Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001;87(4):476–479
  • . Brown BG, Zhao XQ, Chait A, . Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592
  • . Kashyap ML, McGovern ME, Berra K, . Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(6):672–678

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.